Effect of polaprezinc vs zinc acetate dihydrate in Patients Receiving Hemodialysis With Zn deficiency; a single center, open label, randomized clinical study
- Conditions
- Patients on maintenance hemodialysis with zinc deficiency
- Registration Number
- JPRN-UMIN000031200
- Lead Sponsor
- Hirosaki University Graduate School of Medicine
- Brief Summary
The ZAH and PPZ groups had 44 and 47 patients, respectively. At 3 months, the change rate of serum zinc levels in the ZAH group was significantly higher than that in the PPZ group. Three months after the study, serum copper levels significantly decreased in the ZAH group, but not in the PPZ group. No significant differences were noted in anemia management in either group. ZAH was superior to PPZ in increasi
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 91
Not provided
1. Hemodialysis vintage of <6 months 2. Already priscribed polaprenzinc or zinc acetate dihydrate 3. Unwillingness to participate in the study 4. Recent active infection 5. End stage of malignancy 6. Previous history of blood transfusion within at least 3 months before the trial 7. Severe liver damage 8. Drug/alcohol abuse 9. Patients who are not appropriate for the tial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The cahnge in the serum levels of zinc 6 months after the trial
- Secondary Outcome Measures
Name Time Method The change in Erythropoeisis stimulant agent resistance 6 months after the trial The change in the serum levels of copper 6 months after the trial